NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.00 +0.35 (+2.24 %)
(As of 05/24/2018 02:30 AM ET)
Previous Close$15.65
Today's Range$15.55 - $16.20
52-Week Range$6.55 - $27.50
Volume1.48 million shs
Average Volume2.33 million shs
Market Capitalization$1.57 billion
P/E Ratio-22.86
Dividend YieldN/A
Beta2.83

About Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics logoSangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive SGMO News and Ratings via Email

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SGMO
CUSIP80067710
Phone510-970-6000

Debt

Debt-to-Equity Ratio0.14
Current Ratio4.78
Quick Ratio4.78

Price-To-Earnings

Trailing P/E Ratio-22.86
Forward P/E Ratio-29.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$36.57 million
Price / Sales44.41
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book8.89

Profitability

EPS (Most Recent Fiscal Year)($0.70)
Net Income$-54,560,000.00
Net Margins-126.96%
Return on Equity-30.96%
Return on Assets-20.75%

Miscellaneous

Employees182
Outstanding Shares101,500,000

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics Inc (NASDAQ:SGMO) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.52. The biopharmaceutical company earned $12.60 million during the quarter, compared to the consensus estimate of $53.09 million. Sangamo Therapeutics had a negative net margin of 126.96% and a negative return on equity of 30.96%. Sangamo Therapeutics's quarterly revenue was up 270.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.23) earnings per share. View Sangamo Therapeutics' Earnings History.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Sangamo Therapeutics.

What price target have analysts set for SGMO?

5 brokerages have issued 1 year target prices for Sangamo Therapeutics' shares. Their forecasts range from $8.00 to $30.00. On average, they expect Sangamo Therapeutics' share price to reach $22.20 in the next year. View Analyst Ratings for Sangamo Therapeutics.

What are Wall Street analysts saying about Sangamo Therapeutics stock?

Here are some recent quotes from research analysts about Sangamo Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. " (5/16/2018)
  • 2. Wedbush analysts commented, "We traveled with VBI management last week in Boston and noted good reception and enthusiasm around the lead program Sci-B-Vac for Hepatitis B. Enrollment is proceeding well in Phase 3, which we anticipate could be complete during 2Q18. VBI still expects top-line Phase 3 data in mid-2019, which we expect to easily show non- inferiority to GSK’s Engerix-B, and which could show superiority in adults age 45 or older. Interestingly, VBI will also measure seroprotection after 2 doses of Sc-B-Vac vs 3 doses of Engerix-B, which we expect to be positive for Engerix-B as well. In our view, over the long-term, Sci-B-Vac could show a profile suggesting 2 dose protection in patients of all ages, greatly expanding the market opportunity, which we conservatively project to be $370M WW." (3/13/2018)

Are investors shorting Sangamo Therapeutics?

Sangamo Therapeutics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 11,950,598 shares, an increase of 20.7% from the March 30th total of 9,901,110 shares. Based on an average daily volume of 2,446,250 shares, the short-interest ratio is presently 4.9 days. Approximately 14.1% of the company's shares are short sold.

Who are some of Sangamo Therapeutics' key competitors?

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the folowing people:
  • Alexander D. Macrae Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Kathy Y. Yi, Chief Financial Officer, Senior Vice President (Age 45)
  • Heather D. Turner, Senior Vice President, General Counsel (Age 43)
  • Edward R. Conner M.D., Senior Vice President and Chief Medical Officer (Age 44)
  • Curt Herberts III, Senior Vice President and Chief Business Officer (Age 36)
  • Roger Jeffs Ph.D., Director
  • Joseph S. Zakrzewski, Director (Age 54)
  • Robert F. Carey, Independent Director (Age 58)
  • Stephen G. Dilly M.D. Ph.D., Independent Director (Age 57)
  • Steven J. Mento Ph.D., Independent Director (Age 65)

Has Sangamo Therapeutics been receiving favorable news coverage?

News articles about SGMO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a news sentiment score of 0.21 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 45.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.68%), Wasatch Advisors Inc. (4.24%), Alexandria Capital LLC (0.87%), Nexthera Capital LP (0.77%), Wells Fargo & Company MN (0.64%) and Opaleye Management Inc. (0.61%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Institutional Ownership Trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., American Century Companies Inc., Altrinsic Global Advisors LLC, Spark Investment Management LLC, Opaleye Management Inc., Alexandria Capital LLC and Wells Fargo & Company MN. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Curt A Herberts III, Edward R Conner, Kathy Yi, Saira Ramasastry, Steven J Mento and William R Ringo. View Insider Buying and Selling for Sangamo Therapeutics.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., UBS Group AG, Foresite Capital Management III LLC, Artal Group S.A., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Federated Investors Inc. PA and Sector Gamma AS. View Insider Buying and Selling for Sangamo Therapeutics.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $16.00.

How big of a company is Sangamo Therapeutics?

Sangamo Therapeutics has a market capitalization of $1.57 billion and generates $36.57 million in revenue each year. The biopharmaceutical company earns $-54,560,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 182 workers across the globe.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]


MarketBeat Community Rating for Sangamo Therapeutics (SGMO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  470
MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote "Outperform" if you believe SGMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sangamo Therapeutics (NASDAQ:SGMO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Sangamo Therapeutics in the last 12 months. Their average twelve-month price target is $22.20, suggesting that the stock has a possible upside of 38.75%. The high price target for SGMO is $30.00 and the low price target for SGMO is $8.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.832.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.20$22.20$19.80$18.60
Price Target Upside: 38.75% upside14.62% downside20.64% downside23.18% upside

Sangamo Therapeutics (NASDAQ:SGMO) Consensus Price Target History

Price Target History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/13/2018WedbushReiterated RatingHold$8.00MediumView Rating Details
2/25/2018BarclaysReiterated RatingBuy$30.00LowView Rating Details
2/23/2018Jefferies GroupReiterated RatingBuyLowView Rating Details
1/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00HighView Rating Details
9/5/2017Wells Fargo & CoReiterated RatingOutperform$20.00 ➝ $30.00LowView Rating Details
3/22/2017CowenReiterated RatingBuyHighView Rating Details
8/4/2016Janney Montgomery ScottDowngradeBuy ➝ Neutral$15.00 ➝ $8.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Sangamo Therapeutics (NASDAQ:SGMO) Earnings History and Estimates Chart

Earnings by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.08)($0.08)($0.08)
Q2 20182($0.12)$0.03($0.05)
Q3 20182$0.03$0.10$0.07
Q4 20182($0.07)$0.03($0.02)

Sangamo Therapeutics (NASDAQ SGMO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.17)N/AView Earnings Details
5/8/2018Q1 2018$0.29($0.23)$53.09 million$12.60 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.18)($0.1540)$11.10 million$13.08 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.19)($0.15)$10.37 million$11.81 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.17)$5.82 million$8.30 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.26)($0.23)$4.14 million$3.40 millionViewN/AView Earnings Details
2/28/2017Q416($0.26)($0.14)$3.91 million$8.90 millionViewListenView Earnings Details
10/26/2016Q316($0.25)($0.27)$4.24 million$2.82 millionViewListenView Earnings Details
8/3/2016Q216($0.24)($0.38)$5.38 million$3.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.24)($0.23)$5.49 million$3.94 millionViewN/AView Earnings Details
2/9/2016Q415($0.21)($0.20)$9.86 million$9.10 millionViewN/AView Earnings Details
10/28/2015Q315($0.25)($0.13)$13.09 million$8.57 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.17)$14.72 million$8.36 millionViewListenView Earnings Details
4/22/2015Q115($0.13)($0.08)$12.50 million$13.50 millionViewListenView Earnings Details
2/10/2015Q414($0.09)($0.06)$14.50 million$15.00 millionViewN/AView Earnings Details
10/22/2014Q314($0.04)($0.11)$8.27 million$12.40 millionViewListenView Earnings Details
7/23/2014Q214($0.14)($0.10)$7.84 million$10.38 millionViewListenView Earnings Details
5/6/2014Q114($0.13)($0.12)$6.59 million$8.10 millionViewListenView Earnings Details
2/11/2014Q413($0.10)($0.13)$8.90 million$6.90 millionViewListenView Earnings Details
10/23/2013Q313($0.11)($0.11)$5.52 million$5.70 millionViewN/AView Earnings Details
7/24/2013Q2 2013($0.12)($0.10)$4.77 million$6.90 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.17)($0.13)$3.79 million$4.60 millionViewN/AView Earnings Details
2/6/2013Q4 2012($0.12)($0.07)$5.95 million$8.93 millionViewN/AView Earnings Details
10/24/2012Q312($0.14)($0.11)$3.80 million$4.90 millionViewN/AView Earnings Details
7/25/2012($0.15)($0.11)ViewN/AView Earnings Details
5/2/2012($0.16)($0.14)ViewN/AView Earnings Details
2/8/2012Q4 2011($0.13)($0.12)ViewN/AView Earnings Details
10/25/2011($0.16)($0.18)ViewN/AView Earnings Details
7/27/2011($0.16)($0.20)ViewN/AView Earnings Details
4/26/2011($0.17)($0.21)ViewN/AView Earnings Details
2/2/2011($0.19)($0.18)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.15)($0.19)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.08)($0.09)ViewN/AView Earnings Details
5/3/2010Q1 2010($0.09)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.07)($0.05)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.13)($0.12)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.15)($0.11)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.10)($0.17)ViewN/AView Earnings Details
2/4/2009Q4 2008($0.15)($0.06)ViewN/AView Earnings Details
10/29/2008Q3 2008($0.17)($0.15)ViewN/AView Earnings Details
7/23/2008Q2 2008($0.17)($0.18)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.16)($0.20)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.12)($0.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sangamo Therapeutics (NASDAQ:SGMO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 56.37%
Insider Trading History for Sangamo Therapeutics (NASDAQ:SGMO)
Insider Trading History for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ SGMO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018Kathy YiCFOSell5,000$15.38$76,900.0012,250View SEC Filing  
5/7/2018Edward R. ConnerVPSell5,000$16.36$81,800.00View SEC Filing  
4/16/2018Kathy YiCFOSell5,000$19.83$99,150.0012,250View SEC Filing  
4/13/2018Curt A Herberts IIIVPSell8,163$20.00$163,260.0022,788View SEC Filing  
4/6/2018Edward R. ConnerVPSell5,000$17.41$87,050.00View SEC Filing  
4/2/2018Curt A Herberts IIIVPSell2,278$18.30$41,687.40View SEC Filing  
4/2/2018Steven J MentoDirectorSell7,215$18.40$132,756.00View SEC Filing  
3/15/2018Kathy YiCFOSell5,000$25.56$127,800.0012,250View SEC Filing  
3/6/2018Edward R. ConnerVPSell5,000$24.78$123,900.00View SEC Filing  
3/1/2018Curt A Herberts IIIVPSell15,000$23.06$345,900.0014,796View SEC Filing  
3/1/2018Steven J MentoDirectorSell9,433$23.27$219,505.918,480View SEC Filing  
2/26/2018Saira RamasastryDirectorSell9,450$24.88$235,116.009,450View SEC Filing  
2/6/2018Edward R. ConnerVPSell5,000$18.49$92,450.00View SEC Filing  
2/1/2018Curt A Herberts IIIVPSell15,000$20.59$308,850.0029,625View SEC Filing  
2/1/2018Steven J MentoDirectorSell11,520$20.59$237,196.805,000View SEC Filing  
1/8/2018Edward R. ConnerVPSell5,000$17.11$85,550.00View SEC Filing  
1/3/2018Curt A Herberts IIIVPSell15,000$17.26$258,900.0013,015View SEC Filing  
12/6/2017Edward R ConnerVPSell5,000$16.24$81,200.005,000View SEC Filing  
12/4/2017Curt A Herberts IIIVPSell11,803$18.00$212,454.0027,636View SEC Filing  
12/1/2017Curt A. Herberts IIIVPSell16,630$16.13$268,241.90View SEC Filing  
11/17/2017Saira RamasastryDirectorSell5,000$14.67$73,350.005,000View SEC Filing  
10/2/2017Curt A Herberts IIIVPSell15,000$15.25$228,750.00View SEC Filing  
9/20/2017William R RingoDirectorSell31,000$14.37$445,470.0031,800View SEC Filing  
9/1/2017Curt A Herberts IIIVPSell15,000$15.00$225,000.0015,833View SEC Filing  
8/14/2017Curt A Herberts IIIVPSell11,474$10.44$119,788.5623,991View SEC Filing  
7/14/2017Curt A Herberts IIIVPSell15,000$10.00$150,000.0035,517View SEC Filing  
6/1/2017Curt A. Herberts IIIVPSell2,000$6.80$13,600.00View SEC Filing  
5/12/2017Curt A. Herberts IIIVPSell2,639$8.02$21,164.78View SEC Filing  
8/1/2015Ra Capital Management, LlcMajor ShareholderSell27,770$12.82$356,011.40View SEC Filing  
7/30/2015Ra Capital Management, LlcMajor ShareholderSell109,590$12.42$1,361,107.80View SEC Filing  
7/29/2015Ra Capital Management, LlcMajor ShareholderSell1,407$12.41$17,460.87View SEC Filing  
7/28/2015Ra Capital Management, LlcMajor ShareholderSell60,081$12.11$727,580.91View SEC Filing  
7/25/2015Ra Capital Management, LlcMajor ShareholderSell47,429$12.31$583,850.99View SEC Filing  
7/24/2015Ra Capital Management, LlcMajor ShareholderSell124,050$12.28$1,523,334.00View SEC Filing  
7/17/2015Ra Capital Management, LlcMajor ShareholderBuy37,215$12.26$456,255.90View SEC Filing  
7/15/2015Edward O Lanphier IICEOSell25,000$10.43$260,750.00View SEC Filing  
7/13/2015Henry Ward WolffCFOSell12,000$10.00$120,000.00View SEC Filing  
7/1/2015Ra Capital Management, LlcMajor ShareholderSell82,700$16.01$1,324,027.00View SEC Filing  
6/16/2015Ra Capital Management, LlcMajor ShareholderSell250,500$16.55$4,145,775.00View SEC Filing  
6/9/2015Ra Capital Management, LlcMajor ShareholderSell83,500$15.50$1,294,250.00View SEC Filing  
6/6/2015Ra Capital Management, LlcMajor ShareholderSell135,101$14.29$1,930,593.29View SEC Filing  
6/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
6/5/2015Ra Capital Management, LlcMajor ShareholderSell115,102$14.13$1,626,391.26View SEC Filing  
6/4/2015Ra Capital Management, LlcMajor ShareholderSell70,640$13.10$925,384.00View SEC Filing  
6/3/2015Ra Capital Management, LlcMajor ShareholderSell76,833$12.86$988,072.38View SEC Filing  
6/3/2015William R RingoDirectorSell2,200$12.44$27,368.00View SEC Filing  
6/1/2015Philip D GregorySVPSell15,000$12.39$185,850.00View SEC Filing  
5/30/2015Ra Capital Management, LlcMajor ShareholderSell65,884$13.40$882,845.60View SEC Filing  
5/29/2015Ra Capital Management, LlcMajor ShareholderSell155,675$13.53$2,106,282.75View SEC Filing  
5/28/2015Ra Capital Management, LlcMajor ShareholderSell148,689$13.43$1,996,893.27View SEC Filing  
5/27/2015Ra Capital Management, LlcMajor ShareholderSell263,437$13.55$3,569,571.35View SEC Filing  
5/23/2015Ra Capital Management, LlcMajor ShareholderSell51,597$13.27$684,692.19View SEC Filing  
5/22/2015Ra Capital Management, LlcMajor ShareholderSell56,396$13.56$764,729.76View SEC Filing  
5/13/2015Ra Capital Management, LlcMajor ShareholderSell56,060$13.12$735,507.20View SEC Filing  
5/12/2015Ra Capital Management, LlcMajor ShareholderSell29,659$13.03$386,456.77View SEC Filing  
5/8/2015Ra Capital Management, LlcMajor ShareholderSell83,300$12.40$1,032,920.00View SEC Filing  
5/7/2015Ra Capital Management, LlcMajor ShareholderBuy35,736$12.09$432,048.24View SEC Filing  
5/5/2015Dale G AndoCMOSell15,000$12.29$184,350.00View SEC Filing  
5/4/2015William R RingoDirectorSell3,000$12.98$38,940.00View SEC Filing  
4/30/2015Ra Capital Management, LlcMajor ShareholderBuy124,500$13.45$1,674,525.00View SEC Filing  
4/28/2015Ra Capital Management, LlcMajor ShareholderBuy74,844$13.29$994,676.76View SEC Filing  
4/25/2015Ra Capital Management, LlcMajor ShareholderBuy166,000$13.63$2,262,580.00View SEC Filing  
4/22/2015Ra Capital Management, LlcMajor ShareholderSell352,750$14.86$5,241,865.00View SEC Filing  
4/17/2015Ra Capital Management, LlcMajor ShareholderBuy41,500$14.02$581,830.00View SEC Filing  
4/16/2015Ra Capital Management, LlcMajor ShareholderSell21,829$14.09$307,570.61View SEC Filing  
4/15/2015Edward O Lanphier IICEOSell25,000$15.33$383,250.00View SEC Filing  
4/15/2015Ra Capital Management, LlcMajor ShareholderBuy21,829$13.16$287,269.64View SEC Filing  
4/14/2015Ra Capital Management, LlcMajor ShareholderSell3,055$14.78$45,152.90View SEC Filing  
4/11/2015Ra Capital Management, LlcMajor ShareholderBuy116,992$14.48$1,694,044.16View SEC Filing  
4/10/2015Henry Ward WolffCFOSell12,000$15.31$183,720.00View SEC Filing  
4/10/2015Ra Capital Management, LlcMajor ShareholderBuy83,000$14.91$1,237,530.00View SEC Filing  
4/9/2015Ra Capital Management, LlcMajor ShareholderSell69,856$16.27$1,136,557.12View SEC Filing  
4/8/2015Ra Capital Management, LlcMajor ShareholderBuy121,876$15.49$1,887,859.24View SEC Filing  
4/7/2015Ra Capital Management, LlcMajor ShareholderBuy33,667$15.42$519,145.14View SEC Filing  
4/6/2015Dale G AndoCMOSell15,000$14.94$224,100.00View SEC Filing  
4/6/2015William R RingoDirectorSell2,200$14.95$32,890.00View SEC Filing  
4/4/2015Ra Capital Management, LlcMajor ShareholderBuy179,031$15.38$2,753,496.78View SEC Filing  
4/3/2015Ra Capital Management, LlcMajor ShareholderBuy195,126$16.61$3,241,042.86View SEC Filing  
4/1/2015Philip D GregorySVPSell15,000$15.15$227,250.00View SEC Filing  
4/1/2015Ra Capital Management, LlcMajor ShareholderSell250,000$18.01$4,502,500.00View SEC Filing  
3/28/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$17.10$1,436,400.00View SEC Filing  
3/27/2015Ra Capital Management, LlcMajor ShareholderBuy256,187$17.65$4,521,700.55View SEC Filing  
3/26/2015Ra Capital Management, LlcMajor ShareholderBuy210,013$18.14$3,809,635.82View SEC Filing  
3/25/2015Ra Capital Management, LlcMajor ShareholderBuy84,000$19.42$1,631,280.00View SEC Filing  
3/21/2015Ra Capital Management, LlcMajor ShareholderBuy101,808$21.22$2,160,365.76View SEC Filing  
3/19/2015Henry Ward WolffCFOSell10,000$18.00$180,000.00View SEC Filing  
3/19/2015Ra Capital Management, LlcMajor ShareholderSell17,808$24.28$432,378.24View SEC Filing  
3/18/2015Ra Capital Management, LlcMajor ShareholderSell84,000$23.74$1,994,160.00View SEC Filing  
3/17/2015Ra Capital Management, LlcMajor ShareholderBuy52,161$23.02$1,200,746.22View SEC Filing  
3/16/2015Edward O Lanphier IICEOSell25,000$17.29$432,250.00View SEC Filing  
3/13/2015Ra Capital Management, LlcMajor ShareholderBuy71,319$22.76$1,623,220.44View SEC Filing  
3/12/2015Ra Capital Management, LlcMajor ShareholderSell123,480$23.40$2,889,432.00View SEC Filing  
3/10/2015Ra Capital Management, LlcMajor ShareholderBuy12,522$22.30$279,240.60View SEC Filing  
3/7/2015Ra Capital Management, LlcMajor ShareholderBuy258,377$22.25$5,748,888.25View SEC Filing  
3/6/2015Ra Capital Management, LlcMajor ShareholderSell61,483$24.10$1,481,740.30View SEC Filing  
3/3/2015Ra Capital Management, LlcMajor ShareholderSell84,000$18.21$1,529,640.00View SEC Filing  
3/3/2015William R RingoDirectorSell2,200$17.21$37,862.00View SEC Filing  
3/2/2015Philip D GregorySVPSell15,000$17.26$258,900.00View SEC Filing  
2/28/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.10$760,200.00View SEC Filing  
2/27/2015Ra Capital Management, LlcMajor ShareholderSell32,196$19.37$623,636.52View SEC Filing  
2/26/2015Ra Capital Management, LlcMajor ShareholderBuy74,194$19.57$1,451,976.58View SEC Filing  
2/20/2015Ra Capital Management, LlcMajor ShareholderSell35,319$18.40$649,869.60View SEC Filing  
2/19/2015Ra Capital Management, LlcMajor ShareholderSell6,720$18.51$124,387.20View SEC Filing  
2/18/2015Ra Capital Management, LlcMajor ShareholderSell11,172$18.11$202,324.92View SEC Filing  
2/14/2015Ra Capital Management, LlcMajor ShareholderSell15,380$18.61$286,221.80View SEC Filing  
2/13/2015Ra Capital Management, LlcMajor ShareholderSell15,409$18.46$284,450.14View SEC Filing  
2/12/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.04$757,680.00View SEC Filing  
2/12/2015Saira RamasastryDirectorSell10,000$15.00$150,000.00View SEC Filing  
2/11/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$19.65$825,300.00View SEC Filing  
2/7/2015Ra Capital Management, LlcMajor ShareholderSell34,688$18.52$642,421.76View SEC Filing  
2/6/2015Ra Capital Management, LlcMajor ShareholderSell7,312$18.42$134,687.04View SEC Filing  
2/5/2015Dale G AndoCMOSell15,000$12.93$193,950.00View SEC Filing  
2/5/2015Ra Capital Management, LlcMajor ShareholderBuy42,000$18.23$765,660.00View SEC Filing  
2/3/2015William R RingoDirectorSell2,200$12.70$27,940.00View SEC Filing  
2/2/2015Philip D GregorySVPSell15,000$12.86$192,900.00View SEC Filing  
1/16/2015Edward O Lanphier IICEOSell25,000$14.22$355,500.00View SEC Filing  
1/12/2015Henry Ward WolffCFOSell12,000$15.87$190,440.00View SEC Filing  
1/5/2015Dale G AndoCMOSell15,000$15.19$227,850.00View SEC Filing  
1/5/2015William R RingoDirectorSell2,200$15.20$33,440.00View SEC Filing  
12/15/2014Edward O Lanphier IICEOSell25,000$15.40$385,000.00View SEC Filing  
12/15/2014John William LarsonDirectorSell10,000$16.28$162,800.00View SEC Filing  
12/9/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
12/1/2014Philip D GregorySVPSell15,000$11.68$175,200.00View SEC Filing  
11/17/2014Edward O Lanphier IICEOSell25,000$11.23$280,750.00View SEC Filing  
11/12/2014John William LarsonDirectorSell10,000$12.00$120,000.00View SEC Filing  
11/3/2014Philip D GregorySVPSell15,000$11.91$178,650.00View SEC Filing  
10/28/2014John William LarsonDirectorSell10,000$12.02$120,200.00View SEC Filing  
10/10/2014Henry Ward WolffCFOSell2,000$10.10$20,200.00View SEC Filing  
10/6/2014Dale G AndoCMOSell15,000$10.72$160,800.00View SEC Filing  
10/1/2014Philip D GregorySVPSell15,000$10.80$162,000.00View SEC Filing  
9/15/2014Edward O Lanphier IICEOSell25,000$12.14$303,500.00View SEC Filing  
9/10/2014Henry Ward WolffCFOSell2,000$12.31$24,620.00View SEC Filing  
9/5/2014Dale G AndoCMOSell15,000$12.20$183,000.00View SEC Filing  
9/4/2014John William LarsonDirectorSell10,000$12.81$128,100.00View SEC Filing  
8/15/2014Edward O Lanphier IICEOSell25,000$13.95$348,750.00View SEC Filing  
8/11/2014Henry Ward WolffCFOSell10,000$14.17$141,700.00View SEC Filing  
8/5/2014Dale G AndoCMOSell15,000$12.99$194,850.00View SEC Filing  
8/4/2014John William LarsonDirectorSell10,000$12.56$125,600.00View SEC Filing  
8/1/2014Philip D GregorySVPSell15,000$12.54$188,100.00View SEC Filing  
7/18/2014Edward O Lanphier IICEOSell25,000$12.16$304,000.00View SEC Filing  
7/10/2014Henry Ward WolffCFOSell15,000$13.26$198,900.00View SEC Filing  
7/1/2014Philip D GregorySVPSell15,000$15.66$234,900.00View SEC Filing  
6/23/2014Saira RamasastryDirectorSell5,550$15.53$86,191.50View SEC Filing  
6/16/2014Edward O Lanphier IICEOSell25,000$16.41$410,250.00View SEC Filing  
6/10/2014Henry Ward WolffCFOSell15,000$15.62$234,300.00View SEC Filing  
6/2/2014Philip D GregorySVPSell15,000$12.85$192,750.00View SEC Filing  
5/15/2014Edward Lanphier IICEOSell25,000$13.14$328,500.00295,000View SEC Filing  
5/1/2014Philip GregorySVPSell15,000$13.68$205,200.00109,347View SEC Filing  
4/28/2014Dale AndoCMOSell15,000$13.64$204,600.0097,015View SEC Filing  
4/28/2014John William LarsonDirectorSell10,000$13.48$134,800.00218,160View SEC Filing  
4/15/2014Edward Lanphier IICEOSell25,000$14.20$355,000.00295,000View SEC Filing  
4/10/2014Henry Ward WolffCFOSell15,000$15.72$235,800.00225,347View SEC Filing  
3/26/2014Dale AndoCMOSell15,000$18.65$279,750.0097,015View SEC Filing  
3/21/2014Philip GregoryInsiderSell15,000$22.38$335,700.00109,347View SEC Filing  
3/17/2014Edward Lanphier IICEOSell50,000$23.22$1,161,000.00295,000View SEC Filing  
3/17/2014Saira RamasastryDirectorSell10,000$23.26$232,600.00View SEC Filing  
3/14/2014Steven MentoDirectorSell6,103$22.77$138,965.3123,563View SEC Filing  
2/18/2014Edward Lanphier IICEOSell50,000$18.09$904,500.00295,000View SEC Filing  
1/27/2014Dale AndoCMOSell15,000$18.58$278,700.0097,015View SEC Filing  
1/10/2014Henry Ward WolffCFOSell10,000$18.69$186,900.00227,347View SEC Filing  
1/2/2014Philip GregoryVPSell15,000$13.56$203,400.00109,347View SEC Filing  
12/26/2013Dale AndoCMOSell15,000$14.37$215,550.0097,015View SEC Filing  
11/15/2013Edward Lanphier IICEOSell25,000$10.11$252,750.00330,000View SEC Filing  
11/5/2013Philip D GregoryVPSell15,000$9.60$144,000.00View SEC Filing  
10/28/2013Dale G AndoCMOSell15,000$10.39$155,850.00View SEC Filing  
10/21/2013Paul B ClevelandDirectorSell10,000$10.93$109,300.00View SEC Filing  
10/15/2013Edward O Lanphier IICEOSell25,000$11.32$283,000.00View SEC Filing  
10/10/2013Henry Ward WolffCFOSell10,000$11.28$112,800.00209,219View SEC Filing  
10/1/2013Philip D GregoryVPSell15,000$10.54$158,100.00View SEC Filing  
9/16/2013Edward Lanphier IICEOSell25,000$11.29$282,250.00330,000View SEC Filing  
9/10/2013Henry Ward WolffCFOSell10,000$10.86$108,600.00View SEC Filing  
9/3/2013Paul ClevelandDirectorSell7,278$10.30$74,963.40View SEC Filing  
9/3/2013Philip GregoryVPSell15,000$10.33$154,950.0090,000View SEC Filing  
8/26/2013Dale AndoCMOSell15,000$10.04$150,600.0084,798View SEC Filing  
8/15/2013Edward Lanphier IICEOSell25,000$10.12$253,000.00330,000View SEC Filing  
8/13/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00209,219View SEC Filing  
8/1/2013Philip GregoryVPSell15,000$9.89$148,350.0090,000View SEC Filing  
7/29/2013Philip D GregoryVPSell15,000$10.04$150,600.00View SEC Filing  
7/26/2013Dale G AndoCMOSell15,000$10.09$151,350.00View SEC Filing  
7/17/2013Edward O Lanphier IICEOSell25,000$10.00$250,000.00View SEC Filing  
7/17/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
7/15/2013Paul B ClevelandDirectorSell8,000$9.59$76,720.00View SEC Filing  
6/3/2013Philip D GregoryVPSell3,000$7.88$23,640.00View SEC Filing  
5/28/2013Dale G AndoCMOSell15,000$8.32$124,800.00View SEC Filing  
4/10/2013Henry Ward WolffCFOSell10,000$10.00$100,000.00View SEC Filing  
12/26/2012Dale G AndoCMOSell17,000$5.92$100,640.00View SEC Filing  
12/3/2012John William LarsonDirectorSell15,000$5.64$84,600.00View SEC Filing  
9/5/2012Dale G AndoCMOSell15,000$5.60$84,000.00View SEC Filing  
9/4/2012John William LarsonDirectorSell15,000$5.30$79,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines

Source:
DateHeadline
Sangamo Therapeutics Inc (SGMO) CFO Kathy Yi Sells 5,000 SharesSangamo Therapeutics Inc (SGMO) CFO Kathy Yi Sells 5,000 Shares
www.americanbankingnews.com - May 16 at 8:35 PM
Sangamo Therapeutics (SGMO) Downgraded to Strong Sell at Zacks Investment ResearchSangamo Therapeutics (SGMO) Downgraded to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:45 PM
BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003
www.reuters.com - May 16 at 8:31 AM
Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application ...Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application ...
www.streetinsider.com - May 16 at 8:31 AM
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell DiseaseBioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
finance.yahoo.com - May 16 at 8:31 AM
Q2 2018 EPS Estimates for Sangamo Therapeutics Inc Decreased by Jefferies Group (SGMO)Q2 2018 EPS Estimates for Sangamo Therapeutics Inc Decreased by Jefferies Group (SGMO)
www.americanbankingnews.com - May 14 at 1:43 AM
DBV Technologies (DBVT) vs. Sangamo Therapeutics (SGMO) Financial ComparisonDBV Technologies (DBVT) vs. Sangamo Therapeutics (SGMO) Financial Comparison
www.americanbankingnews.com - May 14 at 1:19 AM
Zacks: Analysts Anticipate Sangamo Therapeutics Inc (SGMO) Will Post Quarterly Sales of $27.58 MillionZacks: Analysts Anticipate Sangamo Therapeutics Inc (SGMO) Will Post Quarterly Sales of $27.58 Million
www.americanbankingnews.com - May 12 at 3:50 AM
Sangamo Therapeutics Inc (SGMO) to Post Q3 2018 Earnings of $0.10 Per Share, Jefferies Group ForecastsSangamo Therapeutics Inc (SGMO) to Post Q3 2018 Earnings of $0.10 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 11 at 10:07 AM
Zacks Investment Research Downgrades Sangamo Therapeutics (SGMO) to HoldZacks Investment Research Downgrades Sangamo Therapeutics (SGMO) to Hold
www.americanbankingnews.com - May 10 at 7:05 PM
Sangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by BrokeragesSangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 4:37 PM
-$0.07 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter-$0.07 Earnings Per Share Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
www.americanbankingnews.com - May 10 at 9:22 AM
Edited Transcript of SGMO earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of SGMO earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:34 AM
Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of StockInsider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock
www.americanbankingnews.com - May 9 at 8:28 PM
Applied Genetic Technologies (AGTC) vs. Sangamo Therapeutics (SGMO) Head-To-Head ContrastApplied Genetic Technologies (AGTC) vs. Sangamo Therapeutics (SGMO) Head-To-Head Contrast
www.americanbankingnews.com - May 9 at 3:13 AM
Sangamo Therapeutics (SGMO) CEO Sandy Macrae on Q1 2018 Results - Earnings Call TranscriptSangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:29 PM
Sangamo Therapeutics (SGMO) Cut to Buy at ValuEngineSangamo Therapeutics (SGMO) Cut to Buy at ValuEngine
www.americanbankingnews.com - May 8 at 3:29 PM
Sangamo Therapeutics (SGMO) Announces  Earnings Results, Misses Estimates By $0.07 EPSSangamo Therapeutics (SGMO) Announces Earnings Results, Misses Estimates By $0.07 EPS
www.americanbankingnews.com - May 8 at 2:43 PM
Sangamo Therapeutics misses by $0.05, misses on revenueSangamo Therapeutics misses by $0.05, misses on revenue
seekingalpha.com - May 8 at 8:27 AM
Sangamo: The Secondary Was Ill-Timed Or NotSangamo: The Secondary Was Ill-Timed Or Not
seekingalpha.com - May 8 at 8:27 AM
Sangamo: 1Q Earnings SnapshotSangamo: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:27 AM
Sangamo Therapeutics Reports First Quarter 2018 Financial ResultsSangamo Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:27 AM
Sangamo Therapeutics Announces Senior Leadership ChangesSangamo Therapeutics Announces Senior Leadership Changes
finance.yahoo.com - May 3 at 5:16 PM
Sangamo Therapeutics (SGMO) Upgraded to "Strong-Buy" at ValuEngineSangamo Therapeutics (SGMO) Upgraded to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 2 at 11:39 PM
Sangamo Therapeutics Announces First Quarter 2018 Conference Call and WebcastSangamo Therapeutics Announces First Quarter 2018 Conference Call and Webcast
finance.yahoo.com - May 1 at 5:10 PM
Sangamo Therapeutics (SGMO) Upgraded to "Buy" by Zacks Investment ResearchSangamo Therapeutics (SGMO) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - May 1 at 10:02 AM
Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell TherapySangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy
finance.yahoo.com - May 1 at 8:35 AM
Sangamo Therapeutics (SGMO) Downgraded by BidaskClub to "Sell"Sangamo Therapeutics (SGMO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - May 1 at 8:03 AM
Sangamo Therapeutics (SGMO) Set to Announce Earnings on TuesdaySangamo Therapeutics (SGMO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 1 at 5:18 AM
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional SharesSangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 30 at 5:07 PM
Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - April 30 at 5:07 PM
Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat ...Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat ...
www.prnewswire.com - April 29 at 8:35 AM
Sangamo: The Secondary Was Ill-Timed-Or NotSangamo: The Secondary Was Ill-Timed-Or Not
seekingalpha.com - April 28 at 5:07 PM
Comparing Solid Biosciences (SLDB) & Sangamo Therapeutics (SGMO)Comparing Solid Biosciences (SLDB) & Sangamo Therapeutics (SGMO)
www.americanbankingnews.com - April 28 at 9:29 AM
Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-ThalassemiaSangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia
finance.yahoo.com - April 27 at 8:41 AM
Sangamo Therapeutics Inc (SGMO) Short Interest Up 20.7% in AprilSangamo Therapeutics Inc (SGMO) Short Interest Up 20.7% in April
www.americanbankingnews.com - April 26 at 2:22 AM
Watch CRISPR Therapeutics (CRSP)Watch CRISPR Therapeutics (CRSP)
www.baystreet.ca - April 25 at 8:28 AM
Sangamo Therapeutics (SGMO) Commences $200M Public Offering of Common StockSangamo Therapeutics (SGMO) Commences $200M Public Offering of Common Stock
www.streetinsider.com - April 25 at 8:28 AM
$36.08 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter$36.08 Million in Sales Expected for Sangamo Therapeutics Inc (SGMO) This Quarter
www.americanbankingnews.com - April 25 at 5:56 AM
Your Guide to Investing in Zinc-Finger (ZFN) Gene EditingYour Guide to Investing in Zinc-Finger (ZFN) Gene Editing
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics Announces Proposed Public Offering of Common StockSangamo Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics shares fall on announced secondary offeringSangamo Therapeutics shares fall on announced secondary offering
finance.yahoo.com - April 24 at 5:28 PM
Sangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.05 Per ShareSangamo Therapeutics Inc (SGMO) Expected to Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - April 23 at 1:14 AM
BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior ...BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior ...
www.reuters.com - April 19 at 5:31 PM
Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?Reader Inquiry: Is Recent Weakness In Sangamo Therapeutics A Buying Opportunity?
seekingalpha.com - April 19 at 8:26 AM
Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of StockInsider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock
www.americanbankingnews.com - April 18 at 4:10 PM
Curt A. Herberts III Sells 8,163 Shares of Sangamo Therapeutics Inc (SGMO) StockCurt A. Herberts III Sells 8,163 Shares of Sangamo Therapeutics Inc (SGMO) Stock
www.americanbankingnews.com - April 17 at 7:28 PM
Sangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by AnalystsSangamo Therapeutics Inc (SGMO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 15 at 11:29 AM
Has Sangamo Therapeutics Inc (NASDAQ:SGMO) Improved Earnings Growth In Recent Times?Has Sangamo Therapeutics Inc (NASDAQ:SGMO) Improved Earnings Growth In Recent Times?
finance.yahoo.com - April 13 at 8:35 AM
Markets Recovering From Latest Trump TweetstormMarkets Recovering From Latest Trump Tweetstorm
finance.yahoo.com - April 11 at 5:19 PM

SEC Filings

Sangamo Therapeutics (NASDAQ:SGMO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sangamo Therapeutics (NASDAQ:SGMO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sangamo Therapeutics (NASDAQ SGMO) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.